What happens on day 4 of Mounjaro

Why day 4 feels different from days 1 and 2

Tirzepatide is given as a once-weekly subcutaneous injection, and its blood concentration rises quickly in the 24–48 hours after the pen is used. The SURMOUNT-1 trial, which enrolled 2,539 adults with obesity over 72 weeks, documented that gastrointestinal side effects were most common during the first four weeks at any given dose, and particularly in the days immediately after each injection. By the time day 3 moves into day 4, the steepest part of that curve has already passed for most people.

That does not mean day 4 is symptom-free. Nausea is still possible, especially if you ate a heavy or fatty meal in the previous day or two. What tends to shift is the intensity. The sharper waves of queasiness that some people report on the first day or the second give way to something more manageable — a background awareness rather than an active disruption. Some people feel nothing at all on day 4 and find that slightly unsettling, assuming it means the medicine is not working. It almost certainly does not mean that. Tirzepatide acts on GIP and GLP-1 receptors to slow gastric emptying and reduce appetite; these mechanisms continue regardless of whether you are feeling queasy. The absence of side effects is not evidence of absence of effect.

If you want a fuller picture of how the week unfolds, the day-by-day Mounjaro guide covers what to expect from injection day through to the following week.

Appetite changes on day 4: subtle but real

One of the most consistent observations among people taking tirzepatide is that appetite suppression can feel almost unremarkable at first. On day 4 it often presents not as dramatic food aversion but as arriving at lunchtime without the usual urgency, or leaving food on the plate without consciously deciding to. The NHS notes that tirzepatide works partly by signalling fullness earlier and slowing the rate at which the stomach empties, both of which reduce meal size naturally over time.

This subtlety catches people off guard. A common misconception is that if the hunger is not dramatically reduced by day 4, the medicine is failing. In reality, at the 2.5mg starting dose, the prescribing schedule is designed to let your body adapt. The clinical data from SURMOUNT-1 showed progressive, dose-dependent weight reduction across the full 72 weeks; the early weeks are about tolerability, not transformation. The more significant appetite shifts typically build over subsequent weeks as the dose is reviewed and, where appropriate, increased by the prescriber.

Protein-rich meals and adequate hydration both help on day 4 and beyond. When the stomach empties more slowly, it is easier to accidentally under-eat, so keeping meal quality high matters more than meal quantity at this stage. For a broader look at what tirzepatide is doing in the body, the tirzepatide overview covers the mechanism in plain terms.

Side effects that may still be present on day 4

Nausea, loose stools, constipation, indigestion and fatigue are all listed in the NHS's patient information for tirzepatide as common side effects, particularly in the early weeks. On day 4 these are most likely to be mild and fading rather than escalating. Fatigue in particular can linger a little longer than nausea; some people describe feeling slightly flat or low-energy for the first week of a new dose.

Injection-site reactions (redness, mild swelling, brief itching at the site) can also still be present on day 4 if the skin was sensitive to the injection. Rotating sites between the abdomen, thigh and upper arm helps reduce this over time; the Patient Information Leaflet included with your pen gives the detail on correct technique.

A few things are worth mentioning to a prescriber or seeking prompt medical attention for: severe stomach pain that does not ease, particularly if it radiates to the back, is something to act on rather than wait out. The MHRA issued a Drug Safety Update in January 2026 on the risk of acute pancreatitis with GLP-1 medicines, emphasising that while it is infrequent, persistent severe abdominal pain warrants urgent review. Signs of an allergic reaction (significant swelling, breathing difficulty, a widespread rash) also need prompt attention. For a comprehensive breakdown of the side-effect profile, our Mounjaro side effects page covers each one with practical guidance.

What day 4 does not tell you about the bigger picture

Day 4 is genuinely too early to draw conclusions about how well Mounjaro will work for you. The SURMOUNT-1 data showed average weight reductions of around 20–21% at the highest dose over 72 weeks; those results accumulate slowly and dose by dose, not in the first week. Most people will not see meaningful changes on the scales for several weeks, and the prescriber-guided titration schedule means the dose that eventually works best for you may not even be the one you are on right now.

That is not a reason for frustration. It is a reason to note how you are feeling on day 4, stay in touch with your clinical team if anything concerns you, and keep going. If you are mid-treatment and wondering about cost or coverage for ongoing prescriptions, the Mounjaro pricing guide sets out what private treatment typically involves. For anyone still considering whether to start, our weight-loss treatment overview explains how we approach clinical assessment at nume.